Resolutions of the Annual General Meeting 2023 on the Financial Year 2021/2022 of BRAIN Biotech AG
- Executive Board and Supervisory Board discharged with large majority
- Large majorities in the re-election of one member to the Supervisory Board and the election of two new members
- New compensation system for Executive Board approved
At the Annual General Meeting of BRAIN Biotech AG today (Frankfurt Stock Exchange / BNN / ISIN DE0005203947 / WKN 5203949), shareholders approved all proposals of the Executive and Supervisory Board with clear majorities. These items included the discharging of the acts of the Executive Board and the Supervisory Board, the election of two new members to the Supervisory Board and the approval of a new Executive Board compensation system, which links Executive Board compensation stronger to the long-term performance of the company.
New supervisory board elections by the Annual General Meeting had become necessary to fill a total of three Supervisory Board mandates. Dr Georg Kellinghusen, who had been member of the Supervisory Board of BRAIN Biotech AG since 9 March 2017 and its Chairman since 7 March 2019, was no longer available for re-election as he has reached the age limit for supervisory board members.
Dr. Michael Majerus, Munich, Consultant, had been re-elected to the supervisory board. Mrs. Christine Uekert, Berlin, Managing Director nsight consulting GmbH and Dr. Florian Schnabel, Munich, Managing Director MP Beteiligungs-GmbH, had been newly elected at the shareholder meeting as Supervisory Board members. All members have been elected with effect from the end of the AGM on 8 March 2023 until the end of the AGM that passes a resolution concerning the discharge of the Supervisory Board for the fiscal year from 1 October 2025 until 30 September 2026.
Following the Annual General Meeting, the Supervisory Board of BRAIN Biotech AG elected in its constituent meeting Dr. Michael Majerus as its new Chairman. Dr. Anna Carina Eichhorn continues to serve as Deputy Chairman.
Adriaan Moelker, CEO of BRAIN Biotech AG: "I would like to thank the shareholders - also on behalf of my Executive Board colleague Michael Schneiders - for their confidence. Our special thanks go to Dr. Georg Kellinghusen for his many years of service to the company Dr. Kellinghusen has truly made a difference in building BRAIN into what it is today.” Moelker continued: "I am also very pleased that new highly qualified members have been elected to our Supervisory Board and that Dr. Michael Majerus has taken over as Chairman of the Supervisory Board.”
Dr. Michael Majerus, Chairman of the Supervisory Board of BRAIN Biotech AG: "I would like to thank the Annual General Meeting for re-electing me to the Supervisory Board and look forward to my new tasks as Chairman of the Supervisory Board of BRAIN Biotech AG, helping BRAIN Biotech reach its potential and creating substantial value for our shareholders”
A total of 67.48 % of the registered share capital was represented at the virtual Annual General Meeting.
The detailed voting results as well as the presentations of the Executive Board and all other documents relating to the Annual General Meeting are available on the BRAIN Biotech AG website:
https://www.brain-biotech.com/investors/annual-general-meetings/agm-fy-2021-22
Press Image
About BRAIN
BRAIN Biotech AG is a leading European supplier of bio-based products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. The company focuses on the fields of nutrition, health and environment.
BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into three segments: The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in the United Kingdom and production facilities in continental Europe and the United States. The BioScience segment offers research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening. The BioIncubator segment conducts its own R&D projects or those initiated with partners with high value-added potential. A particularly promising incubator project is the development of the Company's own CRISPR-based gene editing technology platform, which is currently being established and expanded by Akribion Genomics (in foundation planning).
Through its own R&D activities, BRAIN Biotech Group is continuously expanding its product portfolio in the field of specialty enzymes and small molecules. The latter are the starting point for screenings, e.g. for novel drug candidates for pharmaceutical applications.
BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities identification number: ISIN DE0005203947 / WKN 520394). The company employs approximately 330 people and generated revenues of EUR 55,3 million in the fiscal year 2022/23.
For more information, please visit: https://www.brain-biotech.com, LinkedIn, Threads and YouTube.
Disclaimer
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.